Cullinan Therapeutics (CGEM) Change in Accured Expenses: 2020-2023
Historic Change in Accured Expenses for Cullinan Therapeutics (CGEM) over the last 4 years, with Dec 2023 value amounting to $5.1 million.
- Cullinan Therapeutics' Change in Accured Expenses rose 219.77% to $5.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $10.1 million, marking a year-over-year increase of 17.82%. This contributed to the annual value of $2.9 million for FY2024, which is 71.21% down from last year.
- Per Cullinan Therapeutics' latest filing, its Change in Accured Expenses stood at $5.1 million for Q4 2023, which was down 2.09% from $5.2 million recorded in Q3 2023.
- Over the past 5 years, Cullinan Therapeutics' Change in Accured Expenses peaked at $5.2 million during Q3 2023, and registered a low of -$2.8 million during Q2 2023.
- Over the past 3 years, Cullinan Therapeutics' median Change in Accured Expenses value was $1.7 million (recorded in 2021), while the average stood at $1.9 million.
- Over the last 5 years, Cullinan Therapeutics' Change in Accured Expenses had its largest YoY gain of 13,304.76% in 2021, and its largest YoY loss of 645.12% in 2021.
- Over the past 4 years, Cullinan Therapeutics' Change in Accured Expenses (Quarterly) stood at -$21,000 in 2020, then soared by 13,304.76% to $2.8 million in 2021, then tumbled by 42.91% to $1.6 million in 2022, then skyrocketed by 219.77% to $5.1 million in 2023.
- Its Change in Accured Expenses was $5.1 million in Q4 2023, compared to $5.2 million in Q3 2023 and -$2.8 million in Q2 2023.